ONO-4059 (hydrochloride) is the hydrochloride salt form of Tirabrutinib. ONO-4059 is a highly selective, orally bioavailable BTK inhibitor (IC50= 2.2 nM) and demonstrated therapeutic efficacy in a mouse arthritis model.
ONO-4059, a BTK inhibitor, has been found to have potential effect against sorts of malignancies by influencing the B-cell development. It is currently under Phase II trail to study its effect against Chronic lymphocytic leukaemia. IC50: 2.2 nM.
Onjisaponin B is extracted from the roots of Polygala tenuifolia. It was able to induce autophagy and accelerate both the removal of mutant huntingtin and A53T α-synuclein, which are highly associated with Huntington disease and Parkinson disease, respectively. It induces autophagy via the AMPK-mTOR signaling pathway. It increased the NGF level and may have potential therapeutic effects for the treatment of Alzheimer disease patients.
Oncrasin-1 is a potent and effective anticancer inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations. It also led to abnormal aggregation of PKCι in nucleus of sensitive cells but not in resistant cells.
ONC206 is an imipiridone derivative that acts as an antagonist of dopamine D2-like receptors (DRD2/3/4). ONC206 inhibited cellular proliferation in a dose-dependent manner in serous endometrial cancer cell lines.
Onalespib, also known as AT13387, is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. AT13387 selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival.
Omeprazole Related Compound 15 is an impurity of Omeprazole. Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Omeprazole Related Compound 10 is an impurity of Omeprazole. Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Omeprazole Impurity 13 is an impurity of Omeprazole. Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Omeprazole EP Impurity I is an impurity of Omeprazole. Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Omeprazole EP Impurity H is an impurity of Omeprazole. Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Omeprazole EP Impurity G is an impurity of Omeprazole. Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Omeprazole EP Impurity F is an impurity of Omeprazole. Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Omeprazole EP Impurity E is an impurity of Omeprazole. Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Omeprazole EP Impurity D is an impurity of Omeprazole. Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Omeprazole EP Impurity C is an impurity of Omeprazole. Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Omeprazole EP Impurity B is an impurity of Omeprazole. Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Omapatrilat, an octahydropyridothiazepine derivative, has been found to be an ACE inhibitor as well as an endopeptidase inhibitor and was once studied in heart failure and hypertension.
Omadacycline hydrochloride is the hydrochloride salt of Omadacycline which is the first intravenous and oral 9-aminomethylcycline in clinical development for multiple infectious disease indications.
OG (Olumacostat glasaretil) is a acetyl-coenzyme A carboxylase inhibitor. Acetyl-COA carboxylase is the key point for the first, rate-limiting step in de novo fatty acid synthesis. OG can inhibit in vitro human sebocyte lipid production, it can also reduce in vivo sebaceous gland size in hamster ears.
Olsalazine Sodium is an anti-inflammatory prodrug, which consists of two 5-ASA moieties linked by an azo bond. It is used in the treatment of inflammatory bowel disease such as ulcerative colitis.
Olodaterol is an ultra-long-acting β adrenoreceptor agonist. It can be used as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD).
Olodaterol is an ultra-long-acting β adrenoreceptor agonist. It can be used as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD).
Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). In May 2016, olmutinib received its first global approval in South Korea for the treatment of EGFR T790M mutation-positive lung cancer. Olmutinib is also a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).
One of the impurities of Olmesartan Medoxomil. Olmesartan Medoxomil is an angiotensin II receptor antagonist which has been used for the treatment of high blood pressure. It is a metabolite of Olmesartan, which is a specific angiotensin II type 1 (AT1) receptor antagonist with antihypertensive effect. hAT1 receptors: IC50 = 6.18 nM.
Olcegepant, also called as BIBN4096BS or BIBN 4096, is the first potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor(IC50= 0.03 nM) and has been shown to block all effects of infused CGRP (2) and should ef
One of the impurities of Olanzapine. Olanzapine interacts with key receptors of interest in schizophrenia, having a nanomolar affinity for dopaminergic, serotonergic, alpha 1-adrenergic, and muscarinic receptors.
Olanzapine EP Impurity B is an impurity of Olanzapine, an antipsychotic medication indicated for the treatment of schizophrenia, bipolar disorder, etc.
OICR-9429 can inhibit the interaction of WDR5 with peptide regions of MLL and histone 3 as a chemical probe. It can reduce viability of acute myeloid leukemia cells and can also disrupt MLL1-RbBP5 interaction.
ODN 1826, a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist that ameliorates cardiac dysfunction after trauma-hemorrhage. ODN 1826 is an excellent immunostimulator that induces NO and iNOS production in the murine model. It enhances cell apoptosis.
ODM-201 is a new-generation, potent and selective androgen receptor (AR) inhibitor which is potential useful for treatment of castration-resistant prostate cancer (CRPC). ODM-201 is a full and high-affinity AR antagonist that, similar to second-generation antiandrogens enzalutamide and ARN-509, inhibits testosterone-induced nuclear translocation of AR.
O-Desmethyl Venlafaxine Cyclic Impurity is a cyclic impurity of O-Desmethylvenlafaxine. Venlafaxine is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class.
A metabolite of Apixaban, a direct factor Xa inhibitor used as an anticoagulant for the prevention of venous thromboembolism and stroke in atrial fibrillation.
Odanacatib, also known as MK-0822, is an inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K, which may result in a reduction in bone resorption, improvement of bone mineral density, and a reversal in osteoporotic changes. Cathepsin K, a tissue-specific cysteine protease that catalyzes degradation of bone matrix proteins such as collagen I/II, elastin, and osteonectin plays an important role in osteoclast function and bone resorption.
